News - Astellas Pharma, Vaccines


Current filters:

Astellas PharmaVaccines

Popular Filters

Negative FDA news for AVEO's tivozanib and Dynavax' hep B vaccine


US biotech firm AVEO Oncology (Nasdaq: AVEO) says that it has received a complete response letter from…

Anti-viralsAstellas PharmaAVEO OncologyBiotechnologyDynavax TechnologiesHeplisavNorth AmericaOncologyPharmaceuticalRegulationtivozanibVaccines

Astellas ends FLT3 deal with Ambit; reports on flu vaccine ASP7374


The US subsidiary of Japanese drug major Astellas Pharma (TYO: 4503) and USA-based privately held firm…

Ambit BiosciencesASP7374Astellas PharmaLicensingOncologyPharmaceuticalquizartinibResearchVaccines

Astellas to use Abbott's CMV assay for vaccine trial


US health care major Abbott Laboratories (NYSE: ABT) says that it has signed an agreement to collaborate…

Abbott LaboratoriesAnti-viralsAstellas PharmaPharmaceuticalResearchTransVaxVaccines

PDUFA Action Date for Astellas enzalutamide; Urogenix facility to close


The US Food and Drug Administration has assigned a Prescription Drug User Fee Act (PDUFA) action date…

Astellas PharmaenzalutamideGenito-urinaryMedivationOncologyPharmaceuticalRegulationResearchUrogenixVaccines

Back to top